中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

评估肝纤维化进展相关的血清标志物研究现状

王燕 陆伦根

引用本文:
Citation:

评估肝纤维化进展相关的血清标志物研究现状

详细信息
  • 中图分类号: R575.2

The current research on evaluating the progress of liver fibrosis by serum markers

  • 摘要: 肝纤维化是各种慢性肝病重要的病理特征,也是进一步向肝硬化发展的必经阶段,早期诊断和治疗对阻止肝纤维化发展为肝硬化具有重要意义。肝活检仍是诊断肝纤维化的金标准,但具有创性,不易动态观察,临床应用受到限制,因此需寻求理想的无创诊断方法。在过去的十年中,肝纤维化进展相关的血清标志物研究取得了很大的进展,为肝纤维化的无创诊断带来了新希望。

     

  • [1]Bonis PA, Friedman SL, Kaplan MM.Is liver fibrosis reversible?[J].N Engl J Med, 2001, 344 (6) :452-454.
    [2]Friedman SL.Mechanisms of hepatic fibrogenesis[J].Gastroenter-ology, 2008, 134 (6) :1655-1669.
    [3]Novo E, Parola M.Redox mechanisms in hepatic chronic wound healingand fibrogenesis[J].Fibrogenesis Tissue Repair, 2008, 1 (1) :5.
    [4]Borkham-Kamphorst E, Claudia RC, van Roeyen CR, et al.Pro-fibrogenic potential of PDGF-D in liver fibrosis[J].J Hepatol, 2007, 46 (6) :1064-1074.
    [5]Zhou K, Gao CF, Zhao YP, et al.Simpler score of routine labora-tory tests predicts liver fibrosis in patients with chronic hepatitis B[J].J Gastroenterol Hepatol, 2010, 25 (9) :1569-1577.
    [6]Gressner OA, Weiskirchen R, Gressner AM.Biomarkers of liver fi-brosis:clinical translation of molecular pathogenesis or based on liv-er-dependent malfunction tests[J].Clin Chim Acta, 2007, 381 (2) :107-113.
    [7]Giannini E, Caglieris S, Ceppa P, et al.Serum pro-collagen IIIpeptide levels are related to lobular necrosis in untreated patientswith chronic hepatitis C[J].Eur Gastroenterol Hepatol, 2001, 13 (2) :137-141.
    [8]Degott C, Zafrani ES, Callard P, et al.Histopathological study of pri-mary biliary cirrhosis and the effect of ursodeoxycholic acid treatment onhistology progression[J].Hepatology, 1999, 29 (4) :1007-1012.
    [9]George DK, Ramm GA, Walker NI, et al.Elevated serum type IVcollagen:a sensitive indicator of the presence of cirrhosis in haemo-chromaosis[J].J Hepatol, 1999, 31 (1) :47-52
    [10]Murawaki Y, Ikuta Y, Okamoto K, et al.Diagnostic value of serummarkers of connective tissue turnover for predicting histological stag-ing and grading in patients with chronic hepatitis C[J].J Gastroen-terol, 2001, 36 (6) :399-406.
    [11]Saitou Y, Shiraki K, Yamanaka Y, et al.Noninvasive estimation ofliver fibrosis and response to interferon therapy by a serum fibrogen-esis marker, YKL-40, in patients with HCV-associated liver dis-ease[J].World J Gastroenterol, 2005, 11 (4) :476-481.
    [12]Johansen JS.Studies on serumYKL-40 as a biomarker in diseaseswith inflammation, tissue remodelling, fibroses and cancer[J].DanMed Bull, 2006, 53 (2) :172-209.
    [13] Walsh KM, Timms P, Campbell S, et al.Plasma levels of matrixmetalloproteinase-2 (MMP-2) and tissue inhibitors of metallo-proteinases-1 and-2 (TIMP-1 and TIMP-2) as noninvasivemarkers of liver disease in chronic hepatitis C:comparison usingROC analysis[J].Dig Dis Sci, 1999, 44 (3) :624-630.
    [14]Quan TE, Cowper S, Wu SP, et al.Circulating fibrocytes:collagen-secreting cells of the peripheral blood[J].Int J Biochem Bio, 2004, 36 (4) :598-606.
    [15]Gressner OA, Gressner AM.Connective tissue growth factor:a fi-brogenic master switch in fibrotic liver diseases[J].Liver Int, 2008, 28 (8) :1065-1079.
    [16]Tacke F, Gabele E, Bataille F, et al.Bone morphogenetic protein7 is elevated in patients with chronic liver disease and exerts fibro-genic effects on human hepatic stellate cells[J].Dig Dis Sci, 2007, 52 (12) :3404-3415.
    [17]Camps J, Marsillach J, Joven J.Measurement of serum paraoxonase-1 activity as a potential biomarker for chronic liver impairment[J].Clin Chim Acta, 2007, 386 (1-2) :114-115.
    [18]Kuhn J, Gressner OA, Gotting C, et al.Increased serum xylosyl-transferase activity in patients with liver fibrosis[J].Clin Chim Ac-ta, 2009, 409 (1-2) :123-126.
    [19]Schttler M, Müller S, Schn S, et al.Serum xylosyltransferase Iactivity, the new biochemical fibrosis marker, is not affected by renalinsufficiency[J].Clin Biochem, 2005, 38 (5) :486-488.
    [20]Poon TC, Hui AY, Chan HL, et al.Prediction of l iver fibrosis andcirrhosis in chronic hepatitis B infection by serum proteomic F Inger-printing:a pilot study[J].Clin Chem, 2005, 51 (2) :328-335.
    [21]Callewaert N, VLierberghe HV, Hecke AV, et al.Noninvasive diag-nosis of liver cirrhosis using DNA sequencer-based total serum pro-tein glycomics[J].Nat Med, 2004, 10 (4) :429-434.
    [22]Zeng MD, Lu LG, Mao YM, et al.Prediction of significant Fibrosisin HBeAg-Positive Patients with Chronic Hepatitis B by a Noninva-sive Modelogy[J].Hepatology, 2005, 42 (6) :1437-1445.
    [23]Franzini M, Corti A, Fornaciari I, et al.Cultured human cells re-lease soluble gamma-glutamyltransferase complexes correspondingto the plasma b-GGT[J].Biomarkers, 2009, 14 (7) :486-492.
    [24]Shaheen AA, Myers RP.Diagnostic accuracy of the aspartate amin-otransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis:a systematic review[J].Hepatology, 2007, 46 (3) :912-921.
    [25]Jacqueminet S, Lebray P, Morra R, et al.Screening for liver fibro-sis by using a noninvasive biomarker in patients with diabetes[J].Clin Gastroenterol Hepatol, 2008, 6 (7) :828-831.
    [26]Poynard T, Ngo Y, Marcellin P, et al.Impact of adefovir dipivoxilon liver fibrosis and activity assessed with biochemical markers (Fi-broTest-ActiTest) in patients infected by hepatitis B virus[J].JViral Hepat, 2009, 16 (3) :203-213.
    [27]Castera L.Transient elastography and other noninvasive tests to as-sess hepatic fibrosis in patients with viral hepatitis[J].J Viral Hep-at, 2009, 16 (5) :300-314.
  • 加载中
计量
  • 文章访问数:  3360
  • HTML全文浏览量:  15
  • PDF下载量:  738
  • 被引次数: 0
出版历程
  • 出版日期:  2011-08-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回